Manages hypertension. ANDA 203561, held by Sciegen Pharms. Hydrochlorothiazide.
As of Nov 16, 2026, ANDA 203561 (Hydrochlorothiazide), held by Sciegen Pharms, was first approved by FDA on Jan 14, 2019, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Hydrochlorothiazide capsules, USP are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, hydrochlorothiazide capsules, USP may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ACE inhibitors. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 14, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrochlorothiazide12.5MG · capsule;oral | Hydrochlorothiazide | Rx |
| Apr 30, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 30, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 14, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters